The percentage of the global population that are using insulin pumps for the treatment of type 1 diabetes (T1D) is expected to significantly increase from 30% in 2020 to 41% in 2030, according to GlobalData. The leading data and analytics company notes that the success of insulin pumps comes from not only their more flexible dosing, but their association with greater glycemic control. GlobalData highlights an exciting example of data, presented by Insulet at the European Association for the Study of Diabetes (EASD), that demonstrates the potential of these products.

Samisha Khangaonkar, Pharma Analyst at GlobalData, comments: “Insulet has showcased positive results for two of the world’s first tubeless pump systems: Omnipod 5 and Omipod DASH. Two studies analysing Omnipod 5’s performance when combined with continuous glucose monitoring (CGM) supported favorable glycemic control in a broad population, when compared to large registries such as the T1D Exchange. These results are exciting because over 90% of T1D patients in the US still experience hypoglycemia, according to GlobalData research.”

GlobalData’s study highlighted that over 27% of T1D patients experienced severe hypoglycemic events, while 54% saw nocturnal hypoglycemia and over 21% suffered from hypoglycemia unawareness. Further, 47% of T1D patients globally are overweight or obese, and only 20–30% meet their glycemic targets.

Khangaonkar adds: “Failure to achieve glycemic control is one of the major barriers to managing T1D. It is also clear from our research that there is a need for continuous glucose monitoring (CGM) for proper management of the disease, a point expressed by key opinion leaders (KOLs) interviewed by GlobalData. Omnipod 5 offers a solution to these needs, as it combines an insulin pump, CGM system, and a controller algorithm to automatically adjust insulin in response to predicted glucose levels. Omnipod 5 can be controlled using a mobile app, eliminating the need for an additional device, and will have the capabilities to connect with the Dexcom CGM and later with Abbott’s FreeStyle Libre.”

Omnipod 5 will be the third commercially available automated insulin delivery (AID) system after Medtronic’s 670G and the Tandem Control-IQ system. However, Omnipod 5 brings the first AID system with a no-tubing pump. The system received breakthrough device designation from the FDA and is currently under premarket review.

Information based on GlobalData’s report, ‘Insulin Pumps and Continuous Glucose Monitors (Diabetes Care Devices) – Global Market Analysis and Forecast Model (COVID-19 Market Impact)’.